Chongqing Lummy Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rongzhao Qiu

Algemeen directeur

CN¥830.8k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.5yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

Nov 15

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Oct 29

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

Oct 01

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Oct 01

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

CEO

Rongzhao Qiu (30 yo)

4.4yrs

Tenure

CN¥830,800

Compensatie

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rongzhao Qiu	General Manager	4.4yrs	CN¥830.80k	geen gegevens
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	geen gegevens
Wen Lai	Financial Director	8.7yrs	CN¥678.40k	geen gegevens
Song Lin	Deputy GM & Director	1.9yrs	CN¥410.20k	geen gegevens
Dan Cui	Deputy GM	6.7yrs	CN¥359.70k	0.0016% CN¥ 81.9k

5.5yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300006 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	geen gegevens
Song Lin	Deputy GM & Director	1.8yrs	CN¥410.20k	geen gegevens
Yuan Yuan	Chairman of Supervisory Board	7.8yrs	geen gegevens	geen gegevens
Xujiang Chen	Independent Director	4.4yrs	CN¥88.50k	geen gegevens
Geng Chen	Independent Director	4.4yrs	CN¥88.50k	geen gegevens
Jiansheng Liang	Chairman	2.9yrs	CN¥729.40k	geen gegevens
Rihua Ou	Director	4.4yrs	geen gegevens	geen gegevens
Weiyan Tang	Director	4.4yrs	geen gegevens	geen gegevens
Changbi Li	Independent Director	4.4yrs	CN¥88.50k	geen gegevens
Huichuan Xu	Employee Supervisor	10.8yrs	geen gegevens	geen gegevens
Mingyue Tan	Supervisor	2.9yrs	geen gegevens	geen gegevens
Hai Run Wang	Director	1.8yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300006 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Chongqing Lummy Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Less than half of directors are independent

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0 in 3Q 2023)

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.048 loss in 2Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd